TY - JOUR AU - Bacon, B. R. AU - Gordon, S. C. AU - Lawitz, E. AU - Marcellin, P. AU - Vierling, J. M. AU - Zeuzem, S. PY - 2011 DA - 2011// TI - Boceprevir for previously treated chronic HCV genotype 1 infection JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1009482 DO - 10.1056/NEJMoa1009482 ID - Bacon2011 ER - TY - JOUR AU - Bochud, P. Y. AU - Bibert, S. AU - Negro, F. AU - Haagmans, B. AU - Soulier, A. AU - Ferrari, C. PY - 2011 DA - 2011// TI - IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C JO - J Hepatol VL - 55 UR - https://doi.org/10.1016/j.jhep.2011.01.050 DO - 10.1016/j.jhep.2011.01.050 ID - Bochud2011 ER - TY - JOUR AU - Castera, L. AU - Vergniol, J. AU - Foucher, J. AU - Bail, B. AU - Chanteloup, E. AU - Haaser, M. PY - 2005 DA - 2005// TI - Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C JO - Gastroenterology VL - 128 UR - https://doi.org/10.1053/j.gastro.2004.11.018 DO - 10.1053/j.gastro.2004.11.018 ID - Castera2005 ER - TY - JOUR AU - Clark, P. J. AU - Thompson, A. J. AU - McHutchison, J. G. PY - 2011 DA - 2011// TI - IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies JO - Am J Gastroenterol VL - 106 UR - https://doi.org/10.1038/ajg.2010.370 DO - 10.1038/ajg.2010.370 ID - Clark2011 ER - TY - JOUR AU - Fischer, J. AU - Bohm, S. AU - Scholz, M. AU - Muller, T. AU - Witt, H. AU - George, J. PY - 2012 DA - 2012// TI - Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection JO - Hepatology VL - 55 UR - https://doi.org/10.1002/hep.25582 DO - 10.1002/hep.25582 ID - Fischer2012 ER - TY - JOUR AU - Ge, D. AU - Fellay, J. AU - Thompson, A. J. AU - Simon, J. S. AU - Shianna, K. V. AU - Urban, T. J. PY - 2009 DA - 2009// TI - Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance JO - Nature VL - 461 UR - https://doi.org/10.1038/nature08309 DO - 10.1038/nature08309 ID - Ge2009 ER - TY - JOUR AU - Holmes, J. A. AU - Desmond, P. V. AU - Thompson, A. J. PY - 2012 DA - 2012// TI - Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? JO - J Viral Hepatitis VL - 19 UR - https://doi.org/10.1111/jvh.12003 DO - 10.1111/jvh.12003 ID - Holmes2012 ER - TY - JOUR AU - Honda, M. AU - Sakai, A. AU - Yamashita, T. AU - Nakamoto, Y. AU - Mizukoshi, E. AU - Sakai, Y. PY - 2010 DA - 2010// TI - Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C JO - Gastroenterology VL - 139 UR - https://doi.org/10.1053/j.gastro.2010.04.049 DO - 10.1053/j.gastro.2010.04.049 ID - Honda2010 ER - TY - JOUR AU - Ioannou, G. N. AU - Beste, L. A. AU - Green, P. K. PY - 2014 DA - 2014// TI - Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans JO - Clin Gastroenterol Hepatol VL - 12 UR - https://doi.org/10.1016/j.cgh.2013.12.011 DO - 10.1016/j.cgh.2013.12.011 ID - Ioannou2014 ER - TY - JOUR AU - Jacobson, I. M. AU - McHutchison, J. G. AU - Dusheiko, G. AU - Bisceglie, A. M. AU - Reddy, K. R. AU - Bzowej, N. H. PY - 2011 DA - 2011// TI - Telaprevir for previously untreated chronic hepatitis C virus infection JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1012912 DO - 10.1056/NEJMoa1012912 ID - Jacobson2011 ER - TY - STD TI - Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N et al (2011) Telaprevir substantially improved SVR rates accross all IL28B genotypes in the ADVANCE trial. J Hepatol 54:Abstract 1369 ID - ref11 ER - TY - JOUR AU - Jensen, D. M. AU - Pol, S. PY - 2012 DA - 2012// TI - IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? JO - Liver Int Off J Int Assoc Study Liver VL - 32 UR - https://doi.org/10.1111/j.1478-3231.2011.02712.x DO - 10.1111/j.1478-3231.2011.02712.x ID - Jensen2012 ER - TY - JOUR AU - Pearlman, B. L. PY - 2012 DA - 2012// TI - Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care JO - Lancet Infect Dis VL - 12 UR - https://doi.org/10.1016/S1473-3099(12)70060-9 DO - 10.1016/S1473-3099(12)70060-9 ID - Pearlman2012 ER - TY - JOUR AU - Pol, S. AU - Aerssens, J. AU - Zeuzem, S. AU - Andreone, P. AU - Lawitz, E. J. AU - Roberts, S. PY - 2013 DA - 2013// TI - Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure JO - J Hepatol VL - 58 UR - https://doi.org/10.1016/j.jhep.2012.12.023 DO - 10.1016/j.jhep.2012.12.023 ID - Pol2013 ER - TY - JOUR AU - Poordad, F. AU - McCone, J. AU - Bacon, B. R. AU - Bruno, S. AU - Manns, M. P. AU - Sulkowski, M. S. PY - 2011 DA - 2011// TI - Boceprevir for untreated chronic HCV genotype 1 infection JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1010494 DO - 10.1056/NEJMoa1010494 ID - Poordad2011 ER - TY - JOUR AU - Poordad, F. AU - Bronowicki, J. P. AU - Gordon, S. C. AU - Zeuzem, S. AU - Jacobson, I. M. AU - Sulkowski, M. S. PY - 2012 DA - 2012// TI - Factors that predict response of patients with hepatitis C virus infection to boceprevir JO - Gastroenterology VL - 143 UR - https://doi.org/10.1053/j.gastro.2012.05.011 DO - 10.1053/j.gastro.2012.05.011 ID - Poordad2012 ER - TY - JOUR AU - Price, J. C. AU - Murphy, R. C. AU - Shvachko, V. A. AU - Pauly, M. P. AU - Manos, M. M. PY - 2014 DA - 2014// TI - Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting JO - Dig Dis Sci VL - 59 UR - https://doi.org/10.1007/s10620-014-3294-0 DO - 10.1007/s10620-014-3294-0 ID - Price2014 ER - TY - JOUR AU - Suppiah, V. AU - Moldovan, M. AU - Ahlenstiel, G. AU - Berg, T. AU - Weltman, M. AU - Abate, M. L. PY - 2009 DA - 2009// TI - IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy JO - Nat Genet VL - 41 UR - https://doi.org/10.1038/ng.447 DO - 10.1038/ng.447 ID - Suppiah2009 ER - TY - JOUR AU - Tanaka, Y. AU - Nishida, N. AU - Sugiyama, M. AU - Kurosaki, M. AU - Matsuura, K. AU - Sakamoto, N. PY - 2009 DA - 2009// TI - Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C JO - Nat Genet VL - 41 UR - https://doi.org/10.1038/ng.449 DO - 10.1038/ng.449 ID - Tanaka2009 ER - TY - JOUR AU - Urban, T. J. AU - Thompson, A. J. AU - Bradrick, S. S. AU - Fellay, J. AU - Schuppan, D. AU - Cronin, K. D. PY - 2010 DA - 2010// TI - IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C JO - Hepatology VL - 52 UR - https://doi.org/10.1002/hep.23912 DO - 10.1002/hep.23912 ID - Urban2010 ER - TY - JOUR AU - Zeuzem, S. AU - Andreone, P. AU - Pol, S. AU - Lawitz, E. AU - Diago, M. AU - Roberts, S. PY - 2011 DA - 2011// TI - Telaprevir for retreatment of HCV infection JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1013086 DO - 10.1056/NEJMoa1013086 ID - Zeuzem2011 ER -